USPTO serial 79402612
CARSGEN
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Dec 9, 2025
- Examiner
- MAHMOUDI, MARIAM AZIZ
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with CARSGEN?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Adam Bell
Adam Bell Bell IP Law58 West Portal Avenue #121San Francisco, CA 94127United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases; drugs for medical purposes, namely, pharmaceutical preparations for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases; biological preparations for medical purposes for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases; medicinal solutions for injection, namely, medicines for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases; biomedicine for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases; blood for medical purposes; pre-filled syringes for medical purposes filled with pharmaceutical preparations for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases; diagnostic preparations for medical purposes; diagnostic biomarker reagents for medical purposes; pharmaceuticals for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases; biological tissue cultures for medical purposes; serotherapeutic medicines for the treatment of tumors, cancer, autoimmune diseases or disorders, inflammatory diseases, cardiovascular diseases, digestive system diseases, diabetes mellitus, endocrine and metabolic diseases, chronic respiratory diseases, nervous system diseases, bone and joint diseases, mental and psychological diseases, chronic kidney diseases, eye and ear diseases, congenital genetic cardiovascular and neurological diseases, infectious diseases, immune system related diseases and disorders, and blood diseases | ACTIVE | — |
| 042 | Scientific research; scientific laboratory services; research and development of new products for others; technical project studies, namely, conducting scientific feasibility studies; technological research in the field of pharmaceutical studies, biotechnology, medicine, immunotherapy; chemical research; chemistry services, namely, chemist services and chemistry consultation; chemical analysis; medical research; medical and scientific research, namely, conducting clinical trials for others; biological research | ACTIVE | — |
| 044 | Medical screening; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; human tissue bank services; alternative medicine services; therapy services, namely, medical therapy, medicine therapy, immunotherapy, cell therapy, gene therapy, antibody therapy, antibody-drug conjugate therapy, radiation therapy, chemotherapy, and stem cell therapy; telemedicine services; health care; medical clinic services | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by CARsgen Therapeutics Co., Ltd
- Other trademarks owned by CARsgen Therapeutics Co., Ltd
- Other trademarks owned by CARsgen Therapeutics Co., Ltd
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named CARSGEN
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jul 9, 2026 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Jun 20, 2026 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Jun 20, 2026 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Mar 9, 2026 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Feb 5, 2026 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Jan 21, 2026 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Jan 21, 2026 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Dec 9, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Dec 9, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Oct 21, 2025 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Oct 21, 2025 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Oct 15, 2025 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Sep 23, 2025 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Sep 23, 2025 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Sep 23, 2025 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Sep 23, 2025 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Sep 23, 2025 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Apr 4, 2025 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Apr 4, 2025 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Apr 4, 2025 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Apr 2, 2025 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Apr 2, 2025 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Apr 2, 2025 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 1, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 1, 2025 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Apr 1, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 1, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 1, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Apr 1, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Nov 17, 2024 | RFNT | REFUSAL PROCESSED BY IB | — |
| Oct 29, 2024 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Oct 29, 2024 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Oct 23, 2024 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Oct 22, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Oct 22, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 23, 2024 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Aug 23, 2024 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 22, 2024 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |